Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish Real-World Population-Based study
Main finding · 4-point MACEResult — go to the resultHazard ratio 1.05 95% CI 0.82–1.34Authors' conclusion
Our findings do not provide evidence of a reduced cardiovascular risk, as assessed by 4-point MACE, with GLP-1RA. In contrast, SGLT2i demonstrated protective effects against heart failure and atrial fibrillation.
Study context
- Population
- Adults with T2D and obesity, Valencia Clinic-Malvarrosa Department electronic databases (2014–2019), SpainFrom 26,944 subjects
- Participants
- 1,848 / 1,848 / 1,848 / 1,848
- Exposure
- GLP-1 RA, SGLT2i and insulin vs other glucose-lowering agents
- Glucagon-like peptide receptor agonists (GLP-1RA)n = 1,848
- SGLT2in = 1,848
- Insulinn = 1,848
- Miscellanyn = 1,848reference
- Outcome
- 4-point MACE: composite of MI, stroke, all-cause mortality and HF
Methodological detailspopulation-based, 1:1:1:1 propensity score matching
- Population-based
- 1:1:1:1 propensity score matching
Main finding
4-point MACE
Hazard ratio
1.05
95% CI 0.82–1.34
GLP-1RAvs Miscellany
HR 1.05 (95% CI 0.82–1.34)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95% CI) | |
|---|---|---|
| HFSGLT2ivs Miscellany | 0.16 (0.05–0.54) | |
| AFSGLT2ivs Miscellany | 0.58 (0.35–0.95) | |
| 0.050.21520Hazard ratio (log scale) |
Individual outcomes
- Insulin had a higher risk for most individual outcomes vs GLP-1RA and SGLT2i
Original publication
Comparison of GLP-1 receptor agonists and other Glucose-Lowering agents on cardiovascular outcomes in individuals with type 2 diabetes and Obesity: A Spanish Real-World Population-Based study. Diabetes Res Clin Pract. Published 22 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →